CFO Buying Against the Tide. RSI Says Oversold.
Abbott's CFO just dropped $201,300 at $91.50 while the stock sits in full technical breakdown mode. RSI at 32 suggests we're deep in oversold territory, but all timeframes are flashing red. This is his first buy on ABT, so he's stepping into new water here. The setup screams contrarian, but those headwinds are real.
The Filing
| Ticker | ABT |
| Company | ABBOTT LABORATORIES |
| Insider | Philip Boudreau, EVP AND CFO |
| Buy amount | $201,300 |
| Filing date | April 27, 2026 |
| Conviction | Interesting · 56/100 |
| Setup type | Contrarian Setup |
Ultimate members received this analysis in real time.